Burning Rock Biotech, Dizal's Non-Small Cell Lung Cancer Treatment , Diagnostic Receives China Marketing Approval

MT Newswires Live10-11

Burning Rock Biotech (BNR) and Dizal said Thursday that China's National Medical Products Administration has granted marketing approval for their jointly developed companion lung cancer diagnostic for the non-small cell lung cancer patients treatment sunvozertinib.

The approval of the companion diagnostic test is the result of the development of Burning Rock's LungCure diagnostic kit and Dizal's sunvozertinib.

The approval was based on the results of a study of sunvozertinib in platinum-based chemotherapy pretreated non-small cell lung cancer patients that met its primary endpoint in 61% of cases.

Price: 3.4500, Change: +0.17, Percent Change: +5.02

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474051813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-11 15:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474051813","market":"nz","top_or_hot":-1,"title":"Burning Rock Biotech, Dizal's Non-Small Cell Lung Cancer Treatment , Diagnostic Receives China Marketing Approval","media":"MT Newswires Live","content":"<html><body><p> Burning Rock Biotech (BNR) and Dizal said Thursday that China's National Medical Products Administration has granted marketing approval for their jointly developed companion lung cancer diagnostic for the non-small cell lung cancer patients treatment sunvozertinib.</p><p>The approval of the companion diagnostic test is the result of the development of Burning Rock's LungCure diagnostic kit and Dizal's sunvozertinib.</p><p>The approval was based on the results of a study of sunvozertinib in platinum-based chemotherapy pretreated non-small cell lung cancer patients that met its primary endpoint in 61% of cases.</p><p>Price: 3.4500, Change: +0.17, Percent Change: +5.02</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Burning Rock Biotech, Dizal's Non-Small Cell Lung Cancer Treatment , Diagnostic Receives China Marketing Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBurning Rock Biotech, Dizal's Non-Small Cell Lung Cancer Treatment , Diagnostic Receives China Marketing Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 15:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Burning Rock Biotech (BNR) and Dizal said Thursday that China's National Medical Products Administration has granted marketing approval for their jointly developed companion lung cancer diagnostic for...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR.AU","symbol_name":"BULLETIN RESOURCES LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2474051813","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474051813","pubTimestamp":1728633425,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Burning Rock Biotech  and Dizal said Thursday that China's National Medical Products Administration has granted marketing approval for their jointly developed companion lung cancer diagnostic for the non-small cell lung cancer patients treatment sunvozertinib.The approval of the companion diagnostic test is the result of the development of Burning Rock's LungCure diagnostic kit and Dizal's sunvozertinib.The approval was based on the results of a study of sunvozertinib in platinum-based chemotherapy pretreated non-small cell lung cancer patients that met its primary endpoint in 61% of cases.Price: 3.4500, Change: +0.17, Percent Change: +5.02","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR.AU":"BULLETIN RESOURCES LTD","BNR":"燃石医学","BK7104":"黄金","BK4139":"生物科技"},"translate_title":"Burning Rock Biotech、Dizal的非小细胞肺癌治疗、诊断获得中国上市批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR.AU":1,"BNR":0.9},"content_text":"Burning Rock Biotech (BNR) and Dizal said Thursday that China's National Medical Products Administration has granted marketing approval for their jointly developed companion lung cancer diagnostic for the non-small cell lung cancer patients treatment sunvozertinib.The approval of the companion diagnostic test is the result of the development of Burning Rock's LungCure diagnostic kit and Dizal's sunvozertinib.The approval was based on the results of a study of sunvozertinib in platinum-based chemotherapy pretreated non-small cell lung cancer patients that met its primary endpoint in 61% of cases.Price: 3.4500, Change: +0.17, Percent Change: +5.02","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474051813"}